Trial intelligence / Profile preview

Myocet plus cyclophosphamide versus Myocet plus metronomic cyclophosphamide in first-line HER2-negative metastatic breast cancer

2012-001325-28Phase 2Completed

Sponsor: GOIM
Start: Jul 2012
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial of doxorubicin and cyclophosphamide in breast cancer (2 arms), sponsored by GOIM. Primary endpoints: Response rate and Quality of life. Started Jul 2012; status: completed.

Drugs

doxorubicincyclophosphamide

Conditions

breast cancer

Beyond the preview

Go deeper on 2012-001325-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-001325-28.